The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
🤔 why jump the gun before researching?
92% of 2021 and 70% of 2022 coded deaths shown here👇
28% rise in fatal breast cancer
70% rise in pancreatic cancer deaths
120% increase in fatal melanomas among men
35% increase in brain cancer deaths among men
58% increase in death by cancers “without site specification
Copy & paste from report Date: 10 October 2023
" In Figure 10 (left) we can observe that the excess deaths rates from malignant breast neoplasms were -5% in 2020,
then rose to about 12% in 2021 and about 28% in 2022. In terms of statistical significance of the excess deaths, we
observe from Figure 10 (right) that for breast cancers, the Z-score in 2020 was only about -2, which is not a strong
negative signal but perhaps something worth investigating in further detail. We speculate that perhaps the Covid-19
pandemic measures, lifestyle changes or misclassification of breast cancer deaths as Covid-19 deaths led to fewer
breast cancer deaths. When looking at changes in the fraction of all deaths attributed to breast cancers, we observe
that breast cancer rates were about 12% lower, with a -4 Z-score which points to a strong effect and corroborates
the previous observations.
In 2021, the Z-score for adjusted death rates was close to 4.0 which is a strong signal. In 2022 the Z-score rose to
about 9.8, which is a very strong signal and indicates that the excess deaths from breast cancers are statistically
significant deviations from the 2010-2019 trend. "
28% rise in fatal breast cancer should get some established pharma wondered about val201.
As we know of, only Adam & Delaware co. TheoremRx palaver like the looks of val201. Did Adams colleagues in AZN show any interest in this wonder candidate?
TheoremRx supposed to be swimming in millions of $$, but cant afford to pay 10-15k for decent company website. their site is up & running on 1 one page only with a menu button on mobiles giving X. possible just paid $150 for this website or the best is they done themselves.
Euda.com
hosted by: Amazon Technologies Inc.
Domain register: Kalkofnsvegur 2, Reykjavik, IS +354.4212434 Iceland
IP: Singapore
they could have left not that website under construction 🤔
what if Singapore Police force after them?
P9, " its all a mere distraction, the focus point here should be will VAL see any cash from THX before funds run out shortly or will in fall on SH to dig deep again" = agree 👌👍. As Nicholas said SuZy gotto come clean with THX communications.
LOI with Val at least include some £££££££££££ to VAL, but that with EUDA wont show any $$$$$$$$$$$$ to EUDA or anything affecting fundamentals of euda. Ceo of 8i/euda set up the company for 5 years & Shark SH of euda like the company keep its statues until 31December 2026 & listed on nasdaq. EUDA received min of 4 nasdaq non-compliance notifications since its merged/changed name 12 months ago. They dont have much choice.
SPAC_Time
•
10 days ago
The link to the prospectus you posted IS NOT for the EUDA - TheoremRx merger !!
That is the prospectus for TMT Acquisition Corp. TMTC, TMTCR, TMTCU on Nasdaq. That is a PUBLICLY TRADED SPAC.
TMT Acquisition IS A SPAC, and is SEEKING A MERGER. It is NOT a fund raise for TheoremRx or Valirx or whatever stock you are so desperately trying to pump here.
This is not a stock pumping forum. Please stop, or you will be banned from posting anything further here.
https://tinyurl.com/5dr4zur4
If memory serves, val201 was peer-viewed live on this platform by Adam Hargreaves. 11+ indications & fantastic response rate of 54.5%. Clx001 was not peer-viewed, the professor invented the peptide with his assistant & published their study in a journal, Val had a look at it and said its good enough for us we`ll have it.